Literature DB >> 24249809

How low to aim in rheumatoid arthritis? Learning from other disciplines.

Duncan Porter1, James Dale, Naveed Sattar.   

Abstract

Treat-to-target strategies have been widely adopted as the standard of care for the management of patients with rheumatoid arthritis. The concept of 'tight control' is prevalent in other disciplines, particularly in diabetes and cardiovascular risk management. In these disciplines, evidence has accumulated that the utility of tight control strategies must be carefully weighed against the disutility that may arise from multiple interventions, particularly in patients at low risk. There is a lively debate in rheumatology circles about whether treatment should be targeted at achieving low disease activity, clinical remission or imaging remission. As rheumatologists we should learn the lessons from other disciplines, and ensure that we expand the evidence base to ensure our recommendations are securely underpinned by robust evidence.

Entities:  

Keywords:  Disease Activity; Rheumatoid Arthritis; Treatment

Mesh:

Substances:

Year:  2013        PMID: 24249809     DOI: 10.1136/annrheumdis-2013-204339

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

Review 1.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Nat Rev Rheumatol       Date:  2015-02-17       Impact factor: 20.543

2.  Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.

Authors:  Patrick Verschueren; Diederik De Cock; Luk Corluy; Rik Joos; Christine Langenaken; Veerle Taelman; Frank Raeman; Isabelle Ravelingien; Klaas Vandevyvere; Jan Lenaerts; Elke Geens; Piet Geusens; Johan Vanhoof; Anne Durnez; Jan Remans; Bert Vander Cruyssen; Els Van Essche; An Sileghem; Griet De Brabanter; Johan Joly; Kristien Van der Elst; Sabrina Meyfroidt; Rene Westhovens
Journal:  Arthritis Res Ther       Date:  2015-04-09       Impact factor: 5.156

Review 3.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

4.  Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis.

Authors:  Fiona M McQueen; Peter Chapman; Terina Pollock; Dena D'Souza; Arier C Lee; Nicola Dalbeth; Lisa Stamp; Karen Lindsay; Anthony Doyle
Journal:  Arthritis Res Ther       Date:  2017-10-24       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.